Why Product Availability Is Not Regulatory Approval

A product page with a price, a checkout button and fast shipping looks official. None of that tells you whether a regulator has reviewed the product. This guide explains why being for sale and being approved are separate facts, and which public records help you tell them apart. Statuses were checked on October 18, 2026.

Being for sale is not a status

For drugs, the starting rule is strict. With limited exceptions, a new drug may not be introduced into interstate commerce without an FDA-approved application in effect ^{Source [1]}. Approval happens only after the FDA's drug center reviews the evidence and decides the benefits outweigh the risks for the intended population ^{Source [2]}.

Selling a product does not trigger that review. A website can list anything; whether the listing is lawful is a separate question that the FDA may only address later, if at all. So the useful question is never "Can I buy it?" but "What status does this exact product have, and who says so?"

Categories with no pre-market approval at all

Some products reach shelves lawfully without any FDA approval, because the law does not ask for one.

• Cosmetics. Cosmetic products and ingredients, other than color additives, do not need FDA approval before they go on the market ^{Source [3]}. A peptide serum on sale has not been reviewed for whether it works.
• Dietary supplements. The FDA does not have the authority to approve supplements before they are marketed, does not test them before they are sold, and often does not know when a new one comes on the market ^{Source [4]}. A collagen powder on sale has not been approved for anything.
• Compounded drugs. These are prepared by pharmacies and outsourcing facilities and are not FDA-approved ^{Source [5]}. Our guide to approved, compounded and unapproved drugs explains the rules they follow.

None of this makes these products illegal or unsafe. It means that their availability carries no information about review, because there was no review to pass.

"Research use only" is the seller's statement

Some peptides are sold with labels such as "research use only" or "not for human consumption." The label describes what the seller says the buyer will do. It is not a regulatory status, and the FDA does not treat it as one.

In a December 2024 warning letter, the FDA reviewed a seller's website and social media. Despite labels reading "research use only," the agency found that the seller's semaglutide, tirzepatide and similar products were intended as drugs for human use, and that they were unapproved new drugs ^{Source [6]}. In an August 2026 letter to another seller, the FDA listed products including semaglutide, tirzepatide, retatrutide and tesamorelin as unapproved new drugs. It said the research-use labeling did not change the products' intended use, and pointed to the seller offering a solvent for preparing the products as further evidence ^{Source [1]}.

One detail in that second letter is worth noticing. Semaglutide and tirzepatide are ingredients of FDA-approved medicines, such as Wegovy and Zepbound ^{Source [7] Source [8]}, yet the seller's products still had no approved application. Approval belongs to a specific product from a specific maker, not to a molecule that anyone can sell. The FDA has also said publicly that it warned companies selling GLP-1 products falsely labeled for research, directly to consumers with dosing instructions, and urged consumers not to buy them ^{Source [9]}.

Public signals you can check

Drugs@FDA

Drugs@FDA lists products approved under FDA applications. Its downloadable data is updated each weekday ^{Source [10]}. Each entry shows the application number, the company, and every product's dosage form and route. Wegovy injection, for example, appears under NDA 215256 as a solution for use under the skin ^{Source [7]}. If the product you are looking at is not the listed product from the listed company, it is not covered by that approval.

Warning letters

The FDA publishes warning letters in a searchable index. A letter shows what the agency found at the time; the FDA notes that later contact with the company may have changed the status of the issues it describes ^{Source [11]}. A letter is a strong signal about a seller's practices on a given date, not a permanent verdict.

Import alerts

An import alert lets the FDA detain future shipments of a product without examining them, after a violation has been found; the importer then has to show the shipment does not have the problem ^{Source [12]}. Import Alert 66-80, for example, covers GLP-1 bulk drug substances. It keeps a "green list" of manufacturers that met the FDA's criteria to be excluded from detention, and was last revised in October 2026 ^{Source [13]}. The FDA describes it as a way to stop GLP-1 ingredients with possible quality concerns from entering the U.S. supply chain ^{Source [9]}.

What these signals cannot tell you

Silence is not approval. Most sellers never receive a warning letter, and most products never appear on an import alert. The absence of a public enforcement record tells you only that you found none. For supplements, the FDA says it often does not even know a new product is on the market ^{Source [4]}.

Approval is not a personal recommendation either. An approved drug is approved for specific uses, forms and routes, and whether it suits a particular person is a question for that person's clinician. We do not give dosing guidance or personal medical advice.

A quick checklist

• Identify the category the seller claims: drug, cosmetic, supplement, compounded preparation or research material.
• For a drug, find the exact product in Drugs@FDA, including its form and route.
• Search the FDA warning letter index for the seller's name.
• Treat "research use only" as a description of the seller's terms, not as a status.
• Note the date you checked. Statuses change.

Our guides on supplier domains and certificates of analysis cover what to check next.